Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera

医学 原发性血小板增多症 怀孕 产科 真性红细胞增多症 单变量分析 流产 妇科 内科学 多元分析 生物 遗传学
作者
Chi-Joan How,Orly Leiva,Thomas Bogue,Geoffrey Fell,Mark Bustoros,Nathan T. Connell,Jean M. Connors,Irene M. Ghobrial,Nancy Higgins,Nicholas A. Jessop,David J. Kuter,Jennifer Lombardi Story,Ann Mullally,Valentina Nardi,Donna Neuberg,Rachel Styles,Jeffrey I. Zwicker,Gabriela Hobbs,Annemarie E. Fogerty
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 4172-4172 被引量:7
标识
DOI:10.1182/blood-2019-127058
摘要

BACKGROUND: Myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET) and polycythemia vera (PV) are commonly diagnosed in the sixth decade, but as many as 20% of patients are younger than 40. This introduces the possibility of pregnancy and need for specialized management. ET/PV patients have a higher risk of pregnancy complications, with a reported 68.5% live birth rate (LBR), and 1.8% and 2.4% risk of major thrombotic and bleeding events respectively. Risk factors for pregnancy complications are conflicting, and further contemporary studies are needed. METHODS: We retrospectively analyzed 130 pregnancies in 58 ET/PV women seen at 3 affiliate hospitals from 1995-2019. Patients were identified using ICD-9/10 codes in the electronic medical record. We analyzed 12 input variables as risk factors associated with first pregnancy complications after MPN diagnosis by univariate logistic regression (α=0.1, type I error rate; Table 1a). Variables with p<0.10 were included in multivariate logistic regression modeling. Cell counts were averaged at baseline, each trimester, delivery, and the postpartum period. RESULTS: The analysis included 53 ET patients and 5 PV patients. Driver mutation status for JAK2, CALR, or MPL was available in 79% of all patients: 60.3% were JAK2+ and 12.1% were CALR+. 2 patients were high-risk by International Prognostic Score of thrombosis (IPSET). Median maternal age was 34, median year of delivery was 2010, and median time between MPN diagnosis and index pregnancy was 3 years. There were no complications in 46% of pregnancies. The LBR was 70%. Aspirin (ASA) and interferon were used in 58.5% and 1.5% of pregnancies, respectively. In the pregnancies that resulted in live birth, postpartum low-molecular-weight heparin (LMWH) was used in 23.5% of cases. Antepartum LMWH was used in 6.9% of cases. PV patients were more likely to be treated with ASA (p=0.039) or postpartum LMWH (p=0.013) compared to ET patients. The most common complication was spontaneous abortion (SAB), defined as fetal loss <20 weeks, which occurred in 24.6% of all cases. Thrombosis and hemorrhage occurred in 2.3% and 6.9% of pregnancies respectively. On univariate analysis, only history of miscarriage prior to MPN diagnosis (13.2% of women) and ASA use during pregnancy were significantly associated with outcomes. On multivariate analysis, history of prior miscarriage remained statistically significant (OR 8.82, p=0.023), while ASA use during pregnancy trended toward improved outcomes (OR 0.33, p=0.12). All other variables were not significantly associated with pregnancy outcomes (Table 1a). Cell counts throughout pregnancy were available in 53 ET patients (Figure 1). There was a significant decline in platelets (p<0.001) from baseline to delivery. The average percent platelet, hemoglobin (Hg), and white blood cell (WBC) change from baseline to delivery was -42.98%, -9.25%, and +35.65%, respectively. The median nadir was at delivery. In 12 women with postpartum labs drawn within one month of delivery, 7 had recovered their platelet counts to at least 75% of their baseline. CONCLUSIONS: In this contemporary analysis of pregnancy outcomes in 130 ET/PV women, we demonstrate that overall prognosis is good, with a LBR of 70%. However, pregnant ET/PV patients remain at high risk, with SAB and complication rates of 24.6% and 54%, and maternal thrombosis and hemorrhage occurring in 2.3% and 6.9% of pregnancies. We show for the first time that prior miscarriage is a significant predictor of pregnancy complication in MPN patients (OR 8.82). Cell counts have never been systematically evaluated in MPN patients throughout pregnancy. We found that platelet counts decrease dramatically, often to normal, in ET. Platelet recovery occurs quickly in the postpartum period, with most patients returning to 75% of their baseline platelet count by one month postpartum. The observed 43% platelet nadir from starting counts to the day of delivery is greater than the expected 20% platelet decrease in the normal pregnant population. This decrease is unlikely to be explained by hemodilution, as the observed Hg decrease in ET patients approximates that seen in normal women. While we found no effect of JAK2 or CALR mutation status on pregnancy complications, it is possible that changes in allele burden influence platelet trends and outcomes. Measuring these changes in available women is the next step in our investigation. Disclosures Bustoros, MD: Takeda: Honoraria. Connell:Michael H. Flanagan Foundation: Membership on an entity's Board of Directors or advisory committees. Connors:Bristol Myer-Squibb: Consultancy, Other: Scientific Ad boards; Portola: Other: scientific ad boards; Abbott: Consultancy; Eli Lilly: Consultancy. Kuter:Argenx: Consultancy, Honoraria, Research Funding; Alnylam: Consultancy, Honoraria, Research Funding; UCB: Consultancy, Honoraria; Takeda (Bioverativ): Consultancy, Honoraria, Research Funding; Actelion (Syntimmune): Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Shire: Consultancy, Honoraria; Shinogi: Consultancy, Honoraria; Agios: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Momenta: Consultancy, Honoraria; Momenta: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Platelet Disorder Support Association: Consultancy, Honoraria; Agios: Consultancy, Honoraria, Research Funding; Caremark: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Dova: Consultancy, Honoraria; Dova: Consultancy, Honoraria; Kyowa-Kirin: Consultancy, Honoraria; Kezar: Research Funding; Bristol Myers Squibb (BMS): Consultancy, Honoraria, Research Funding; Actelion (Syntimmune): Consultancy, Honoraria, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Protalex: Consultancy, Honoraria, Research Funding; Kezar: Research Funding; Platelet Disorder Support Association: Consultancy, Honoraria; Up-to-Date: Consultancy, Honoraria, Patents & Royalties: 3 Up-to-Date chapters; Takeda (Bioverativ): Consultancy, Honoraria, Research Funding; Shire: Consultancy, Honoraria; Rigel: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Rigel: Consultancy, Honoraria, Research Funding; Genzyme: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Shinogi: Consultancy, Honoraria; Genzyme: Consultancy, Honoraria; Merck Sharp Dohme: Consultancy, Honoraria; Protalix: Consultancy, Honoraria; Protalix: Consultancy, Honoraria; Principia: Consultancy, Honoraria, Research Funding; Principia: Consultancy, Honoraria, Research Funding; Protalex: Consultancy, Honoraria, Research Funding; UCB: Consultancy, Honoraria; Up-to-Date: Consultancy, Honoraria, Patents & Royalties: 3 Up-to-Date chapters; Zafgen: Consultancy, Honoraria; Zafgen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Alnylam: Consultancy, Honoraria, Research Funding; Argenx: Consultancy, Honoraria, Research Funding; Merck Sharp Dohme: Consultancy, Honoraria; Kyowa-Kirin: Consultancy, Honoraria; Caremark: Consultancy, Honoraria; Bristol Myers Squibb (BMS): Consultancy, Honoraria, Research Funding. Mullally:Janssen: Research Funding. Neuberg:Pharmacyclics: Research Funding; Madrigal Pharmaceuticals: Equity Ownership; Celgene: Research Funding. Zwicker:Daiichi: Consultancy; Quercegen: Research Funding; Parexel: Consultancy; Portola: Consultancy; Incyte: Research Funding; Seattle Genetics: Consultancy; Bayer: Consultancy. Hobbs:Jazz pharmaceuticals: Consultancy; Bayer: Research Funding; Merck: Research Funding; Celgene: Consultancy; Incyte: Consultancy, Research Funding; Agios: Consultancy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彩色脆霜发布了新的文献求助10
1秒前
www完成签到,获得积分10
1秒前
研友_VZG7GZ的应助被shymuaiu采纳,获得10
2秒前
2秒前
Feny发布了新的文献求助10
2秒前
GingerF的应助被Tuniverse_采纳,获得100
2秒前
科研通AI6.4的应助被miao采纳,获得10
2秒前
2秒前
千贝儿完成签到,获得积分10
2秒前
wy发布了新的文献求助10
3秒前
sunstar完成签到,获得积分10
3秒前
悦耳安萱完成签到 ,获得积分10
3秒前
Ava的应助被111采纳,获得10
4秒前
hui完成签到,获得积分10
4秒前
111发布了新的文献求助10
4秒前
5秒前
5秒前
科研通AI6.3的应助被酱鱼采纳,获得10
6秒前
lunna发布了新的文献求助10
6秒前
ss完成签到,获得积分10
6秒前
学习牛马发布了新的文献求助30
6秒前
7秒前
甘甘甘甘的应助被科研通管家采纳,获得30
7秒前
Jasper的应助被cai采纳,获得10
7秒前
科研通AI2S的应助被科研通管家采纳,获得10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
打打的应助被科研通管家采纳,获得10
8秒前
情怀的应助被科研通管家采纳,获得10
8秒前
04d的应助被科研通管家采纳,获得10
8秒前
田様的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
小蘑菇的应助被wei采纳,获得10
8秒前
852的应助被科研通管家采纳,获得10
8秒前
斯文败类的应助被bam采纳,获得10
8秒前
orixero的应助被科研通管家采纳,获得10
8秒前
香蕉觅云的应助被科研通管家采纳,获得10
9秒前
斯文败类的应助被科研通管家采纳,获得10
9秒前
英俊的铭的应助被科研通管家采纳,获得10
9秒前
酷波er的应助被科研通管家采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192209
求助须知:如何正确求助?哪些是违规求助? 9578801
关于积分的说明 21861940
捐赠科研通 7791695
什么是DOI,文献DOI怎么找? 3436846
关于科研通互助平台的介绍 2560562
邀请新用户注册赠送积分活动 2483617